Tokai Pharmaceuticals, a biotech developing small molecule therapies for prostate cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The company is in Phase 2 trials for its lead candidate, a daily oral treatment that is expected to enter pivotal clinical trials in the 1H15.
The Cambridge, MA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol TKAI. Tokai Pharmaceuticals initially filed confidentially on May 2, 2014. BMO Capital Markets, Stifel and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
